Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
SEOUL, South Korea, July 2, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced a collaboration with Microsoft to accelerate the delivery of AI-powered healthcare solutions. In conjunction with their recent acquisition of Volpara, a Microsoft Industry Health Certified Partner, this collaboration will give...
Bon Announces Breakthrough Order for $16 Million Gut-Health Products
XI'AN, China, July 2, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solutions provider in the natural, health, and personal care industries, today announced a non-exclusive sales distribution agreement with Beijing Huahai Keyuan Technology Co., Ltd., a leading wellness company in China ("Huahai Keyuan"). The term of the agreement is 24 months...
[iNtRON] Files U.S. Patent for Three Novel Endolysin-Based Drug Candidates Targeting Gram-Negative Bacteria
Gram-negative bacterial infections are becoming an increasingly serious global health issue U.S. patent applications filed for three novel drug candidates: PKL200, TSL2200, and EAL2200 Continued diversification of business initiatives to address Gram-negative bacterial threats BOSTON and SEOUL, South Korea, July 2, 2025 /PRNewswire/ -- More than 1,200 reported cases of CRE (Carbapenem-Resistant Enterobacteriaceae) infections have been reported...
Arbele Wins Top Prize at BCIC’s 4th Annual Biomedical Pitch Competition
BOSTON, July 2, 2025 /PRNewswire/ -- Arbele Limited, a Hong Kong-based biotech company, was awarded first place at the 4th Biomedical Pitch Competition, hosted by the Boston Capital Investment Club (BCIC). Selected from over 170 companies across the U.S. and Asia, Arbele stood out for its groundbreaking research in CDH17-targeted immunotherapy and antibody-drug conjugates (ADCs). Arbele is developing novel treatments...
Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52 weeks of follow-up. In Cohort 2, 7 patients completed 52 weeks of follow-up. The updated data showed that EVER001 was well-tolerated and efficacious in patients with pMN. These results support the potential of EVER001...
Field Medical Closes Oversubscribed $35 Million Series B to Advance Development of FieldForce™ Pulsed Field Ablation Platform
BioStar Capital and Cue Growth co-lead financing to accelerate pivotal trial readiness and expand the ventricular tachycardia (VT) treatment market New board leadership reflects Field's momentum and readiness for pivotal execution CARDIFF-BY-THE-SEA, Calif., July 1, 2025 /PRNewswire/ -- Field Medical, Inc., a clinical-stage...
TraceLink’s MINT Named “Supply Chain Transparency Solution of the Year” in 2025 SupplyTech Breakthrough Awards
The award recognizes MINT for enabling real-time, end-to-end visibility across critical supply chain transactions and processes BOSTON, July 1, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, today announced that its Multienterprise Information Network Tower (MINT) solution has been named "Supply Chain...
Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics
Real-time analytics that empower clinical decision-making and pandemic preparedness Global unveiling at ADLM 2025 in Chicago to initiate business partnerships Powered by AI and syndromic PCR to enable early detection and predictive insights SEOUL, South Korea, July 1, 2025 /PRNewswire/ --...
Declare Freedom from Discomfort This July — Bestqool’s Non-invasion Red Light Therapy
Let the light lead the way — this July, give yourself the freedom to feel your best. NEW YORK, July 1, 2025 /PRNewswire/ -- As the fireworks illuminate the night sky this 4th of July, Bestqool invites customers to celebrate independence not only as citizens but also within their own well-being journeys — with powerful tools that enhance vitality,...
Metabolon’s Untargeted Metabolomics Services Used for Breakthrough Study Revealing Powerful Link Between Gut Microbiome, the Metabolome, and Type 2 Diabetes (T2D)
Combining metabolomics, gut microbiome, and clinical data may help prevent and personalize the treatment of type 2 diabetes MORRISVILLE, N.C., July 1, 2025 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision...
